患者由来ヒト大腸上皮オルガノイドの 臨床グレード培養法を確立 -Wnt活性ペプチドにより高効率・高安定な培養を実現し、 消化管再生医療の実用化を加速-

ad

2026-04-27 東京科学大学

東京科学大学と順天堂大学の研究チームは、患者由来のヒト大腸上皮オルガノイドを臨床利用可能な条件で培養する手法を確立した。従来不安定だったWnt3aタンパク質の代替として、Wnt活性ペプチドPG-008を導入することで、すべての症例で安定した初代培養と100倍以上の高い増殖能を実現。幹細胞分画の増幅により、均一かつ高品質なオルガノイドの作製が可能となった。さらにGMPグレードの培養系を採用することで、安全性と再現性を確保しつつ低コスト化にも成功。本技術は潰瘍性大腸炎など難治性疾患に対する再生医療の実用化を加速し、消化管のみならず多様な臓器再生への応用が期待される。

患者由来ヒト大腸上皮オルガノイドの 臨床グレード培養法を確立 -Wnt活性ペプチドにより高効率・高安定な培養を実現し、 消化管再生医療の実用化を加速-
図1. 臨床応用を目指した患者由来ヒト大腸上皮オルガノイド培養法の開発

<関連情報>

ペプチドベースのWntシグナル活性化により、再生細胞療法のための臨床グレードの患者由来腸管オルガノイドの大規模生産が可能になる Peptide-based Wnt signal activation enables scalable production of clinical-grade patient-derived intestinal organoids for regenerative cell therapy

Hady Yuki Sugihara,Sayaka Nagata,Sho Kawasaki,Junichi Takahashi,Yui Hiraguri,Masayoshi Fukuda,Kohei Suzuki,Tatsuro Murano,Satoru Fujii,Toshimitsu Fujii,Hiromichi Shimizu,Kazuo Ohtsuka,Mamoru Watanabe,Ryuichi Okamoto & Tomohiro Mizutani
Stem Cell Research & Therapy  Published:29 March 2026
DOI:https://doi.org/10.1186/s13287-026-04995-6  Unedited version

Abstract

Background

Gastrointestinal diseases often involve cellular damage, degeneration or dysfunction in the tract, frequently requiring surgical interventions risking complications and lowered quality of life. Regenerative medicine holds great promise in improving patient care and providing novel treatment options for previously irreparable and untreatable tissues. Despite the clinical potential of intestinal organoids as a resource for regenerative cell therapy and bioengineering, the lack of clinical-grade cultures has hampered further development. Moreover, strategies to efficiently and reliably expand clinical-grade cultures at the scale required for application is limited.

Methods

A GMP-compliant protocol was developed to generate patient-derived colonic organoids from endoscopic biopsies. Clinical-grade colonic organoids cultured and expanded in Type-I collagen were compared to conventional Matrigel cultured organoids. To improve the culture-, cost-, and time-efficiency of culture expansion, several strategies were developed including organoid area-based passaging, one well plate culture, and the incorporation of Wnt activating peptide, PG-008. Conventional recombinant WNT3A culture was compared to the peptide PG-008 culture using single cell RNA sequencing.

Results

Clinical-grade collagen cultured organoids exhibited similar culture efficiency to Matrigel. Organoid establishment rate from 60 patients using the GMP-compliant protocol was 82%. The incorporation of PG-008 significantly enhanced organoid growth and stabilized patient-patient variability through intestinal stem cell (ISC) enrichment. Single cell RNA sequencing revealed that PG-008 resulted in remarkably pure culture consisting of ISCs and transit amplifying cells, suitable for rapid and consistent expansion. Intriguingly, our GMP-grade colonic organoids contained LGR5+ ISCs, and injury-induced LGR5 regenerative ISCs, both enriched in peptide culture.

Conclusions

Our study establishes clinical-grade colonic organoids for further application, including autologous transplantations and bioengineering. Further, collagen cultured organoids can be a valuable model facilitating in vitro investigations into regenerative stem cell induction and intestinal regeneration.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました